IL6 and rheumatoid arthritis: Prospective studies dissecting the therapeutic effects of CTLA4-Ig on the synovial compartment are needed to confirm the dynamism of CD4pos cell subpopulations and might give novel insights on our data in naïve and established RA patients showing that CTLA-4Ig promotes an immunological re-setting of the deranged immunological balance with particular focus on IL-6 levels and T-Regs that arose as the strongest biomarkers of the clinical outcome.